POSTNEOADJUVANT THERAPY STAGE IVB GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8
Clinical trials for POSTNEOADJUVANT THERAPY STAGE IVB GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new POSTNEOADJUVANT THERAPY STAGE IVB GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8 trials appear
Sign up with your email to follow new studies for POSTNEOADJUVANT THERAPY STAGE IVB GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug targets Hard-to-Treat cancers with specific mutations
Disease control Recruiting nowThis study tests a drug called avapritinib in people with advanced solid tumors that have spread and have specific gene changes (CKIT or PDGFRA mutations). The drug works by blocking enzymes that help cancer cells grow. The goal is to see if avapritinib can shrink or control thes…
Matched conditions: POSTNEOADJUVANT THERAPY STAGE IVB GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 16, 2026 23:55 UTC
-
New combo drug trial hopes to shrink tough cancers
Disease control Recruiting nowThis early-stage study tests a new combination of two drugs (trifluridine/tipiracil and talazoparib) in people with advanced colorectal or gastroesophageal cancers that have spread. The main goals are to find the safest dose and understand side effects. About 45 participants will…
Matched conditions: POSTNEOADJUVANT THERAPY STAGE IVB GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8
Phase: PHASE1 • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated May 15, 2026 11:56 UTC
-
Radiation boosts immune attack on stubborn GI cancers?
Disease control Recruiting nowThis study is for people with advanced gastrointestinal cancers that are spreading and no longer responding to immunotherapy. Researchers want to see if adding targeted radiation to one tumor can help the immune system fight cancer throughout the body. About 28 participants will …
Matched conditions: POSTNEOADJUVANT THERAPY STAGE IVB GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8
Phase: NA • Sponsor: University of California, San Francisco • Aim: Disease control
Last updated May 11, 2026 20:40 UTC
-
New drug combo shows promise for tough stomach cancers
Disease control Recruiting nowThis early-phase study tests two drugs, pembrolizumab and lenvatinib, in about 15 people with advanced stomach or gastroesophageal cancer that has spread or can't be surgically removed. Pembrolizumab helps the immune system attack cancer cells, while lenvatinib blocks enzymes tha…
Matched conditions: POSTNEOADJUVANT THERAPY STAGE IVB GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8
Phase: EARLY_PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 04, 2026 16:23 UTC